Abstract
The results obtained with intensive chemotherapy and intensive chemotherapy plus radiotherapy in non-Hodgkin's lymphomata are reported. A quintuple drug regimen (mechloretamine, adriamycin, bleomycin, vincristine and prednisone) in histiocytic lymphomata (Stage III and IV) yielded complete remissions in 53% and complete plus partial remissions in 77%. These figures were 44% and 64% respectively in lymphocytic lymphoma. In Stage III complete responders after combination chemotherapy were subsequently irradiated (involved field irradiation). The median duration of complete remission after completion of radiotherapy was 9-5 months in histiocytic and 12-0 months in lymphocytic lymphomata. At 2 years actuarial survival in Stage III and IV was better in patients with the lymphocytic type and with nodular pattern than with histiocytic and diffuse patterns. A more recent trial compares, in Stage IV patients, cyclophosphamide, vincristine and prednisone (CVP) versus adriamycin, bleomycin and prednisone (ABP). Although the number of evaluable patients is still limited, there appears to be no difference in the response rate between CVP and ABP. In Stages I and II, 6 cycles of CVP were given as adjuvant treatment after radiotherapy. At the present moment, there is no statistical difference in the relapse rate between the group of patients treated with radiotherapy alone and that with radiotherapy plus CVP.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagley C. M., Jr, Devita V. T., Jr, Berard C. W., Canellos G. P. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med. 1972 Feb;76(2):227–234. doi: 10.7326/0003-4819-76-2-227. [DOI] [PubMed] [Google Scholar]
- Bonadonna G., De Lena M., Monfardini S., Bartoli C., Bajetta E., Beretta G., Fossati-Bellani F. Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer. 1972 Apr;8(2):205–215. doi: 10.1016/0014-2964(72)90045-x. [DOI] [PubMed] [Google Scholar]
- Carbone P. P. Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment. Cancer. 1972 Dec;30(6):1511–1516. doi: 10.1002/1097-0142(197212)30:6<1511::aid-cncr2820300615>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
- Carbone P. P., Spurr C., Schneiderman M., Scotto J., Holland J. F., Shnider B. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res. 1968 May;28(5):811–822. [PubMed] [Google Scholar]
- HICKS E. B., RAPPAPORT H., WINTER W. J. Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer. 1956 Jul-Aug;9(4):792–821. doi: 10.1002/1097-0142(195607/08)9:4<792::aid-cncr2820090429>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- Jones S. E., Kaplan H. S., Rosenberg S. A. Non-Hodgkin's lymphomas. 3. Preliminary results of radiotherapy and a proposal for new clinical trials. Radiology. 1972 Jun;103(3):657–662. doi: 10.1148/103.3.657. [DOI] [PubMed] [Google Scholar]
- Jones S. E., Rosenberg S. A., Kaplan H. S., Kadin M. E., Dorfman R. F. Non-Hodgkin's lymphomas. II. Single agent chemotherapy. Cancer. 1972 Jul;30(1):31–38. doi: 10.1002/1097-0142(197207)30:1<31::aid-cncr2820300106>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
- Luce J. K., Gamble J. F., Wilson H. E., Monto R. W., Isaacs B. L., Palmer R. L., Coltman C. A., Jr, Hewlett J. S., Gehan E. A., Frei E., 3rd Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer. 1971 Aug;28(2):306–317. doi: 10.1002/1097-0142(197108)28:2<306::aid-cncr2820280208>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
- Monfardini S., Tancini G., Gasparini M., Pizzetti F., De Lena M., Bonadonna G. Risposta e sopravvivenza dopo monochemioterapia sequenziale nei linfomi maligni linfocitari ed istiocitari. Tumori. 1973 May-Jun;59(3):219–238. doi: 10.1177/030089167305900304. [DOI] [PubMed] [Google Scholar]